Treatment of Refractory Metastatic Renal Cell Carcinoma

Treatment of Refractory Metastatic Renal Cell Carcinoma

First-line treatment for metastatic renal cell carcinoma (mRCC) rapidly shifted in recent years with the advent of combination therapies, including immune checkpoint inhibitor (ICI) doublets and combinations of an ICI with a vascular endothelial growth factor receptor (VEGFR) targeted tyrosine kinas...

Full description

Bibliographic Details
Main Authors: Joseph A. Vento, Brian I. Rini
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
metastatic renal cell carcinoma
refractory therapies
immune checkpoint inhibition
VEGFR tyrosine kinase inhibitors
new RCC agents
Online Access:https://www.mdpi.com/2072-6694/14/20/5005

Internet

https://www.mdpi.com/2072-6694/14/20/5005

Similar Items